BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olsen HH, Muratov V, Cederlund K, Lundahl J, Eklund A, Grunewald J. Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action. Clin Exp Immunol 2014;177:712-9. [PMID: 24773420 DOI: 10.1111/cei.12360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Thunold RF, Løkke A, Cohen AL, Ole H, Bendstrup E. Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2017;34:2-17. [PMID: 32476819 DOI: 10.36141/svdld.v34i1.5760] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
2 Hijdra D, Vorselaars AD, Crommelin HA, van Moorsel CH, Meek B, Claessen AM, Rijkers GT, Grutters JC. Can intermediate monocytes predict response to infliximab therapy in sarcoidosis? Eur Respir J 2016;48:1242-5. [PMID: 27390275 DOI: 10.1183/13993003.00709-2016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lourda M, Olsson-Åkefeldt S, Gavhed D, Axdorph Nygell U, Berlin G, Laurencikas E, von Bahr Greenwood T, Svensson M, Henter JI. Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis. Blood 2016;128:1302-5. [PMID: 27365427 DOI: 10.1182/blood-2016-03-708107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]